Phase Ib/II Trial of BRAF and EGFR inhibition in BRAFV600E metastatic colorectal cancer and other cancers: EVICT (Erlotinib and Vemurafenib In Combination Trial).

Lavinia Tan Ben Tran Jeanne Tie Benjamin Markman Sumi Ananda Niall C Tebbutt Michael Michael Emma Link Stephen Q Wong Sushma Chandrashekar Jerick Guinto David S Ritchie Rachel M Koldej Benjamin J Solomon Grant A McArthur Rodney John Hicks Peter Gibbs Sarah-Jane Dawson Jayesh Desai

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The EVICT study demonstrated a safe and novel combination of two oral inhibitors targeting BRAF and EGFR. The dynamic assessment of serial ctDNA was a useful measure of underlying genomic changes in response to this combination and in undertsnidng potential mechanisms of resistance.

Keyphrases

metastatic colorectal cancer
epidermal growth factor receptor
small cell lung cancer
phase iii
tyrosine kinase
study protocol
clinical trial
phase ii
advanced non small cell lung cancer
randomized controlled trial
wild type
open label
copy number
cancer therapy
young adults
climate change
circulating tumor